Ligand Pharmaceuticals Inc (LGND): Shareholders' Equity
$1.02B
As of 2025-12-31
$967.52M
As of 2026-06-30
+19.4%
3-year compound annual growth
+7.5%
5-year compound annual growth
+15.7%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.02B | +22.5% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $830.44M | +18.5% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $700.91M | +17.3% | 2026-02-27, Balance as of period end |
| 2022-12-31 | $597.49M | -27.2% | 2025-02-28, Balance as of period end |
| 2021-12-31 | $821.16M | +15.7% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $709.52M | -7.5% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $767.23M | +36.8% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $560.91M | +40.3% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $399.79M | +17.1% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $341.29M | +43.8% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $237.28M | +801.6% | 2017-02-28, Balance as of period end |
| 2014-12-31 | $26.32M | -47.0% | 2016-11-14, Balance as of period end |
| 2013-12-31 | $49.61M | +87.3% | 2015-02-23, Balance as of period end |
| 2012-12-31 | $26.48M | +223.6% | 2014-12-12, Balance as of period end |
| 2011-12-31 | $8.19M | n/m | 2013-03-14, Balance as of period end |
| 2010-12-31 | -$4.85M | n/m | 2012-11-14, Balance as of period end |
| 2009-12-31 | $3.74M | n/a | 2012-11-14, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.02B | +22.5% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $307.42M | +453.3% |
| Harrow, Inc. (HROW) | 2025-12-31 | $52.45M | -24.7% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $433.90M | -22.8% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $364.05M | -13.6% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $631.00M | +30.1% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $13.69M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $303.13M | -47.0% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | -$261.83M | n/m |
Compare LGND, VREOF, HROW, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗